Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Mylan Pharmaceuticals Inc., a subsidiary of Mylan Inc. (MYL - Analyst Report), recently announced that it has launched its generic version of Sanofi's (SNY - Analyst Report) Avapro (irbesartan) 75 mg, 150 mg and 300 mg tablets after receiving final approval from the US Food and Drug Administration (FDA).

Avapro is used for hypertension and type II diabetic nephropathy. According to IMS Health, Avapro (75 mg, 150 mg and 300 mg tablets), generated US revenues of approximately $400.7 million for the 12 months ending June 30, 2012.

Meanwhile, Mylan has also launched its generic version of Sanofi’s Avalide (150/12.5mg and 300/12.5 mg), a fixed-dose combination of Avapro and a diuretic (hydrochlorothiazide) for initial use in patients with hypertension, who might need several drugs control their blood pressure. According to IMS Health, Avalide (150/12.5mg and 300/12.5 mg tablets), generated US revenues of approximately $117.4 million for the 12 months ending June 30, 2012.

Apart from Mylan, several other generic manufacturers including Sandoz, the generic division of Novartis (NVS - Snapshot Report) and Dr. Reddy's Laboratories Ltd. (RDY - Snapshot Report) have received approval for their generic versions of Avapro and Avalide. We note that Teva Pharmaceutical Industries Ltd. (TEVA - Analyst Report) was the first to receive approval for Avapro and Avalide in April 2012 and enjoyed a 180-day period of marketing exclusivity.

As of September 28, 2012, Mylan had 168 ANDAs pending FDA clearance, targeting $79 billion in branded sales annually. Mylan believes that about 33 of these pending abbreviated new drug applications (ANDAs) are first-to-file opportunities, representing approximately $20.7 billion in branded sales. The revenue figures are as per IMS Health for the 12 months ending June 30, 2012.

Our Recommendation

We are encouraged by Mylan’s geographic reach and product depth along with a robust generic product pipeline. However, we remain concerned about the company’s lackluster performance in the Europe, Middle East and Africa (EMEA) region.

Additionally, with most large branded drugs due to lose patent exclusivity within the 2017-2018 period, we have little visibility on the growth prospects of generic companies like Mylan beyond that timeframe.

Thus, we prefer to remain on the sidelines and have a Neutral recommendation on Mylan. The stock carries a Zacks #2 Rank (Buy rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%